3-SCREEN-SOLUTIONS
24.8.2021 09:02:12 CEST | Business Wire | Press release
3 Screen Solutions (3SS) and KAONMEDIA (KOSDAQ: KAON MEDIA) jointly announce the completion of their hybrid STB (set-top box) integration for Nordic pay-TV giant Allente .
This accomplishment is a milestone achievement which makes Allente one of the world’s first operators to complete Google Common Broadcast Stack integration for an Android TV Operator Tier STB. The project was completed in just six months thanks to close collaboration between Allente, KAONMEDIA , NAGRA , Broadcom , 3SS and Google .
The partnership of 3SS and KAON to deliver Allente’s new service was announced in October 2020. Powerful hybrid KAON BCM72180 PVR STBs will be available to Allente’s over 1 million subscribers, with NAGRA Media CAS, Broadcom 72180 SoC and based on 3SS UX technology, in Q3 2021.
Google created its standardized Common Broadcast Stack (CBS) to accelerate the reach of Android TV OS worldwide. Announced in October 2020, CBS will help more TV viewers to get the next-generation app-rich services they crave. A Broadcast Stack is the software designed for STBs and other TV devices that enables playing and recording of digital TV broadcast signals. Among the positive outcomes of adopting CBS are easier and faster integration for hybrid Android TV OS devices, accelerated time-to-market, simplified upgrades and reduced overall TCO (total cost of ownership). Additionally, with CBS being collectively optimized through Google’s wide-ranging tech partner network, service providers and their subscribers can be even more confident of a superior, next-level Android TV OS viewing experience.
“We congratulate Allente for becoming one of the first operators in the world to leverage the Common Broadcast Stack, and in working closely with world-class technology partners, elevating the digital entertainment user experience for consumers,” commented Matthias Puschmann, Strategic Android TV Partner Development Manager at Google.
The Nordic region’s pre-eminent pay-TV provider, Allente is further building upon its first successful 3SS-enabled project. OnePlace is the satellite and OTT service which Canal Digital launched in February 2018 . In 2019 the service was named “Best TV User Experience” in the prestigious CSI Awards . Allente was later formed from the merger of Viasat Consumer and Canal Digital in May 2020, and offers TV via satellite, streaming and other services including IPTV and fibre broadband via open networks to customers in Norway, Sweden, Denmark and Finland.
Allente’s new hybrid KAON BCM72180 PVR STB will give subscribers a range of benefits from high performance to a proven next-gen 3SS-engineered customer experience.
Jon Espen Nergård, Allente CTO, said, “Completion of our STB integration so rapidly is a clear testament to the technology, engineering skill and dedication to customer satisfaction from our partners KAON and 3SS, and indeed those of our wider partnership of collaborators which includes NAGRA, Broadcom and of course Google.”
KAON STB middleware is fully integrated with the Android TV software stack to enable new pre-certified Android TV capabilities such as Custom Over-The-Air Update, among others, further accelerating the introduction of new appealing features.
“We are extremely proud to be the first OEM to complete STB integration on a Broadcom SoC with NAGRA CAS seamlessly integrated with UX delivered by 3SS,” commented Tom Buhl, KAON Media Executive Vice President. “The rapid pace of integration with our highly esteemed partners could hardly be more powerful evidence of the many benefits made possible by the Google Common Broadcast Stack,” he added.
“Our ongoing partnership of trust with Allente is a source of tremendous pride for the entire team at 3SS,” commented Kai-Christian Borchers, Managing Director of 3SS. “In becoming one of the world’s first service providers to embrace Google’s Common Broadcast Stack, Allente is blazing a new trail in innovation and customer focus; we eagerly anticipate helping Allente to deliver leading-edge viewing to consumers in the Nordic region,”
SAFe means speedy integration
This project was accelerated thanks to modern principles of agile development , which were first introduced to Canal Digital by 3SS. At the heart is “SAFe” (Scaled Agile Framework), the practical experience-based software development framework which accelerates and optimizes system deployments.
With SAFe, all stakeholders in a project, both in-house and partners, know the status of objectives and exactly where they are in the progress of a granular roadmap of deliverables. SAFe delivers accelerated, streamlined innovation, better productivity, effective planning and superior products.
Google, Google Play and Android TV are trademarks of Google LLC.
About Allente
Allente is a leading Nordic TV operator, providing top quality TV and broadband services to over 1 million customers in Norway, Sweden, Denmark and Finland. The company was established in May 2020 by a merger between Canal Digital and Viasat Consumer. In 2020, the two companies had combined net sales of SEK 7 billion. Allente is owned 50/50 by Telenor Group and NENT Group. www.allente.se
About KAON
KAON is a technology leader in pay-TV and broadband solutions. We ensure the connected home technology which enables consumers to simply change the way they experience entertainment and information within the home with the full line-up of innovative platforms and service solutions to give users easy access to multi-screen experiences anywhere, at any time. KAONMEDIA is well recognized by Tier 1 Operators in more than 90 countries. Headquartered in South Korea, KAONMEDIA has global presence in over 24 countries including Germany, Norway, France, Spain, Netherlands, Australia, USA, Brazil, Mexico, Colombia, Japan, and others. www.kaonmedia.com
About 3 Screen Solutions (3SS)
Since 2009, 3SS
has been delivering world-class software solutions to service providers and technology innovators to bring video to any screen. 3SS is an acknowledged leader in system integration, app development, UI/UX design innovation and solution architecture. 3SS designs and engineers front end and back end platforms for major operators and broadcasters worldwide to make customer experiences easier and more personal. 3SS’ customers include major satellite, cable, IPTV, OTT and mobile TV operators, including Swisscom, Com Hem (Tele2), Allente, Proximus, TCC Uruguay, FreeCast (SelectTV), Altibox, ORS (simpliTV), Yes (STINGTV), Vodafone Kabel Deutschland, Stofa, Liberty Global (UPC, Unitymedia), SES, Eutelsat, and O2/Telefonica. Broadcast customers include ProSiebenSat.1, Joyn (ProSiebenSat.1/Discovery), SUPER RTL (TOGGO), n-tv, Blockbuster and Viacom, among others. 3ss.tv
, 3ready.tv
View source version on businesswire.com: https://www.businesswire.com/news/home/20210824005029/en/
Link:
Social Media:
https://www.facebook.com/allentesverige
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom